Details of the Drug Combination

General Information of Drug Combination (ID: DC95HWJ)

Drug Combination Name

PMID28870136-Compound-43 Mebutamate

Indication

Disease Entry	Status	REF
Chronic myelogenous leukemia	Investigative	[1]

Component Drugs

PMID28870136-Compound-43 DMWGV8N

Mebutamate DM0KYI4

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: KBM-7

Zero Interaction Potency (ZIP) Score: 10.5

Bliss Independence Score: 10.5

Loewe Additivity Score: 27.13

LHighest Single Agent (HSA) Score: 27.15

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

PMID28870136-Compound-43 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Ecto-5'-nucleotidase (CD73)	TTK0O6Y	5NTD_HUMAN	Inhibitor	[3]
------------------------------------------------------------------------------------

Indication(s) of Mebutamate

Disease Entry	ICD 11	Status	REF
Anxiety disorder	6B00-6B0Z	Approved	[2]

Mebutamate Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
GABA(A) receptor gamma-3 (GABRG3)	TTEX6LM	GBRG3_HUMAN	Modulator	[4]
------------------------------------------------------------------------------------

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.